TIAM2
ENSC icon

Tru Independence Asset Management 2’s Ensysce Biosciences ENSC Stock Holding History

Tru Independence Asset Management 2’s Portfolio ENSC Stock Details ENSC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7K Buy
13,000
+1,000
+8% +$634 ﹤0.01% 82
2025
Q4 		$11K Buy
12,000
+1,500
+14% +$2.78K 0.01% 86
2025
Q3 		$24.9K Buy
+10,500
New +$22.6K 0.02% 86

Other funds holding ENSC

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Tru Independence Asset Management 2's ENSC Position: Q1 2026 in Review

Tru Independence Asset Management 2 increased its Ensysce Biosciences (ENSC) stake by 8.3% in Q1 2026, buying an estimated $634 and bringing the position to 13,000 shares worth $7K. The position accounts for ﹤0.01% of the portfolio, ranked #82.

Tru Independence Asset Management 2 first reported a position in ENSC in Q3 2025 and has held it in 3 quarters since. The position peaked at $24.9K in Q3 2025. 15 funds tracked by Wall St. Rank hold ENSC as of Q1 2026.

  • Tru Independence Asset Management 2 held 13,000 shares of Ensysce Biosciences worth $7K as of Q1 2026.
  • Tru Independence Asset Management 2 bought 1,000 Ensysce Biosciences shares in Q1 2026, an estimated $634.
  • Ensysce Biosciences made up ﹤0.01% of Tru Independence Asset Management 2's portfolio in Q1 2026, its #82 holding.
  • Tru Independence Asset Management 2 first reported a position in Ensysce Biosciences in Q3 2025 and has held it in 3 quarters since.
  • Tru Independence Asset Management 2's Ensysce Biosciences position peaked at $24.9K in Q3 2025.
  • 15 funds tracked by Wall St. Rank held Ensysce Biosciences as of Q1 2026.

Based on Tru Independence Asset Management 2's 13F filing for Q1 2026, filed 22 Apr 2026.